Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Kelly

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancerAnna M Sawka, Sharon Straus, Lorne Rotstein, et al.
Journal of the American College of Cardiology|July 2, 2016
Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 DiabetesEylem Levelt, Michael Pavlides, Rajarshi Banerjee, et al.
Molecular Genetics and Metabolism|July 2, 2025
The mitochondrial disease biomarker GDF15 is dynamic, quantifiable in saliva, and correlates with disease severityQiuhan Huang, Caroline Trumpff, Anna S Monzel, et al.
Stroke|March 13, 2023
Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled TrialMelissa D Stockbridge, Jordan Elm, Bonnie L Breining, et al.
Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Digital Medicine|June 21, 2023
Deep-learning-enabled brain hemodynamic mapping using resting-state fMRIXirui Hou, Pengfei Guo, Puyang Wang, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trialAriadna Tibau, M Teresa Martínez, Manuel Ramos, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancerAnna M Sawka, Sharon Straus, Lorne Rotstein, et al.
Journal of the American College of Cardiology|July 2, 2016
Ectopic and Visceral Fat Deposition in Lean and Obese Patients With Type 2 DiabetesEylem Levelt, Michael Pavlides, Rajarshi Banerjee, et al.
Molecular Genetics and Metabolism|July 2, 2025
The mitochondrial disease biomarker GDF15 is dynamic, quantifiable in saliva, and correlates with disease severityQiuhan Huang, Caroline Trumpff, Anna S Monzel, et al.
Stroke|March 13, 2023
Transcranial Direct-Current Stimulation in Subacute Aphasia: A Randomized Controlled TrialMelissa D Stockbridge, Jordan Elm, Bonnie L Breining, et al.
Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast CancerTiffany A Traina, Kathy Miller, Denise A Yardley, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Digital Medicine|June 21, 2023
Deep-learning-enabled brain hemodynamic mapping using resting-state fMRIXirui Hou, Pengfei Guo, Puyang Wang, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Quality of life with palbociclib plus fulvestrant <i>versus</i> placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trialAriadna Tibau, M Teresa Martínez, Manuel Ramos, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
Pageof 7